Addex Therapeutics Ltd. has released promising results from its novel γ-aminobutyric acid subtype B receptor (GABA-B) positive allosteric modulator (PAM) chronic cough program. In models of chronic cough in guinea pigs, the candidate GABA-B PAM significantly and dose-dependently reduced citric acid-induced cough frequency and increased cough latency.
The hypothalamus controls several neural circuits that have to do with instinctive behaviors such as food seeking, socialization and offspring maternal care, among others. There is limited knowledge regarding the mechanisms by which internal and external sensory cues are integrated to coordinate innate behavior.
The big advantage of cell culture to model diseases is its throughput. “You can play the disease over and over again in the dish,” Clive Svendsen told the audience at the International Society of Stem Cell Research (ISSCR) Annual Meeting held in Hamburg last week. That high throughput, however, is not particularly useful if the cell lines themselves do not accurately model the disease. Cancer cell lines are used in many cell culture experiments far beyond cancer for their ability to grow. But they are “highly abnormal,” Bill Skarnes told the audience at an innovation showcase, as well as quite unstable. “I don’t think the [HEK-293] cell line is the same in your lab as it is in the lab next door,” Skarnes said.
Shenzhen Yangli Pharmaceutical Technology Co. Ltd. has patented poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer, ischemia and neurodegeneration.
Adlai Nortye Biopharma Co. Ltd. has divulged molecular glue degraders acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be useful for the treatment of cancer, viral infections, autoimmune disease and inflammatory disorders.
Onquality Pharmaceuticals China Ltd. has described cyclin-dependent kinase 4 (CDK4) and/or cyclin-dependent kinase 6 (CDK6) inhibitors reported to be useful for the treatment of cancer therapy-associated disorders.
Jiangsu Vcare Pharmatech Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
Researchers from the Chinese Academy of Sciences evaluated the highly potent and selective inhibitor of the second bromodomain (BD2) of the bromodomain and extra-terminal (BET) family of proteins, ABBV-744, with the aim of assessing its preclinical efficacy and exploring the pathways by which the compound regulates microglia-mediated neuroinflammation.
CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYS-6016, the company’s mRNA respiratory syncytial virus (RSV) vaccine.
RSS
